TFF Pharmaceuticals Announces Positive Initial Data from Ongoing Phase 2 Trials of TFF VORI and TFF TAC
Treatment with TFF VORI resulted in positive treatment outcomes based on clinical, mycologic and radiologic responses while maintaining a favorable safety/tolerability profile, with no all-cause mortality, no invasive pulmonary aspergillosis (IPA)-related mortality, and no TFF VORI discontinuations due to an adverse event (AE)
Related news for (TFFP)
- TFF Pharmaceuticals Announces It Will Wind Down Operations
- tff pharmaceuticals’ technology generates superior inhalational dry powder formulations for pulmonary drug delivery
- tff pharmaceuticals announces positive preclinical data from bivalent universal influenza vaccine candidates manufactured by tff following intranasal immunization
- tff pharmaceuticals to present at the h.c. wainwright 26th annual global investment conference
- TFF Pharmaceuticals to Present Data from Phase 2 Trial of Voriconazole Inhalation Powder (TFF VORI) for the Treatment of Invasive Pulmonary Aspergillosis at the 11th Advances Against Aspergillosis & Mucormycosis Conference